OCGN
Bearish signalScored 2026-10-15 Drivers: trend, fundamentals. Insiders: neutral. Moteurs : tendance, fondamentaux. Initiés : neutre.
Research, not advice.
À propos
Ocugen, Inc.
- Nom
- Ocugen, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $250.8M
- Employés
- 116
- PDG
- Shankar Musunuri
- Site web
- https://www.ocugen.com
- Marché
- ADCTALMSCMPXFULCLCTXLXRX
Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and Leber congenital amaurosis. OCU410: Another gene therapy candidate, currently being developed to address dry age-related macular degeneration (AMD). OCU200: A novel fusion protein, presently undergoing preclinical evaluation for its potential in treating diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen maintains significant strategic collaborations, including a partnership with CanSino Biologics Inc. for the joint development and manufacturing of gene therapies, and an alliance with Bharat Biotech for the commercialization of COVAXIN within the United States market. The company's corporate headquarters are situated in Malvern, Pennsylvania.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 937 454 titres (~970 264,89 $ US)
- Insiders
- Musunuri Shankar
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$970,265
Avg sell (VWAP, 90d window) $1.04 vs last close $0.79 (-23.9%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$970,265 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-10-09
- Liquidity
- Thin $5,394,850/day · 20d vol
- Last synced
-
2026-10-19 21:10:46
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-09 | Musunuri Shankar | Sell · S S · 10b5-1 | 468,727 | $0.95 | ≈ $445,291 | Form 4 |
| 2026-09-09 | Musunuri Shankar | Sell · S S · 10b5-1 | 468,727 | $1.12 | ≈ $524,974 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2022-11-08 | Chris Jacobs | Sale (Full) | $1,001 - $15,000 |
Signal
Bearish signalScored 2026-10-15 Drivers: trend, fundamentals. Insiders: neutral. Moteurs : tendance, fondamentaux. Initiés : neutre.
OCGN presents a deeply distressed financial profile with near-insolvency indicators (current ratio ~1.0, negative equity, deeply negative cash flow) that overwhelm the modest catalytic signals from the OCU400 MENA…
The first sentence of the analysis written for OCGN on 2026-10-15 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Unavailable or mixed. – Insider: neutral. All sales (≈ $970K) were pre-planned Rule 10b5-1 trades, excluded from the score. No open-market buys or discretionary sales. – Initiés : neutre. Toutes les ventes (≈ $970K) sont sous plan 10b5-1 préétabli, exclues du score. Aucun achat ni vente discrétionnaire.
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Pulls against a bullish reading. Current ratio 1.06 · operating margin -1426%
Suggested stop 0.69, 1.5 ATR under the last close(12.6% under the last close). Reward/risk to the next stored resistance is 2.31. Research, not advice. Not an order.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 45.9% | 51.5% | 88.3% | 100.0% | 0.0% | |
| Ebit Margin | -1419.9% | -1333.0% | -1045.0% | -3488.9% | 0.0% | |
| Ebitda Margin | -1365.7% | -1284.5% | -1033.4% | -3469.6% | 0.0% | |
| Operating Profit Margin | -1425.7% | -1350.4% | -1085.7% | -3580.0% | 0.0% | |
| Pretax Profit Margin | -1537.4% | -1333.0% | -1045.0% | -3488.9% | 0.0% | |
| Continuous Operations Profit Margin | -1537.4% | -1333.0% | -1045.0% | -3488.9% | 0.0% | |
| Net Profit Margin | -1537.4% | -1333.0% | -1045.0% | -3488.9% | 0.0% | |
| Bottom Line Profit Margin | -1537.4% | -1333.0% | -1045.0% | -3488.9% | 0.0% | |
| Current Ratio | 1.056 | 2.857 | 2.515 | 3.452 | 14.664 | |
| Quick Ratio | 1.056 | 2.857 | 2.515 | 3.452 | 14.664 | |
| Solvency Ratio | -1.176 | -0.986 | -2.601 | -2.491 | -5.847 | |
| Cash Ratio | 0.806 | 2.710 | 2.309 | 2.719 | 13.565 | |
| Price To Earnings Ratio | -5.870 | -4.025 | -2.212 | -3.250 | -15.167 | |
| Price To Earnings Growth Ratio | -0.391 | 0.174 | 0.063 | -0.097 | 4.702 | |
| Forward Price To Earnings Growth Ratio | -0.391 | 0.174 | 0.063 | -0.097 | 4.702 | |
| Price To Earnings Diluted Ratio | -5.870 | -4.025 | -2.212 | -3.250 | -15.167 | |
| Price To Earnings Diluted Growth Ratio | -0.391 | 0.174 | 0.063 | -0.097 | 4.702 | |
| Price To Book Ratio | -33.308 | 7.362 | 3.463 | 3.771 | 9.260 | |
| Price To Sales Ratio | 91.826 | 53.798 | 23.275 | 112.130 | 0.000 | |
| Price To Free Cash Flow Ratio | -7.091 | -4.792 | -1.937 | -4.323 | -18.153 | |
| Price To Operating Cash Flow Ratio | -7.114 | -5.177 | -2.264 | -4.644 | -18.508 | |
| Debt To Assets Ratio | 0.762 | 0.394 | 0.108 | 0.059 | 0.031 | |
| Debt To Equity Ratio | -2.724 | 1.097 | 0.171 | 0.086 | 0.035 | |
| Debt To Capital Ratio | 1.580 | 0.523 | 0.146 | 0.079 | 0.033 | |
| Long Term Debt To Capital Ratio | 1.791 | 0.480 | 0.065 | 0.030 | 0.018 | |
| Financial Leverage Ratio | -3.577 | 2.782 | 1.591 | 1.468 | 1.104 | |
| Working Capital Turnover Ratio | 0.213 | 0.123 | 0.126 | 0.030 | 0.000 | |
| Operating Cash Flow Ratio | -2.472 | -1.952 | -3.631 | -2.106 | -6.849 | |
| Operating Cash Flow Sales Ratio | -12.908 | -10.393 | -10.281 | -24.148 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.003 | 1.080 | 1.169 | 1.074 | 1.020 | |
| Debt Service Coverage Ratio | -9.361 | -39.281 | 0.000 | 0.000 | -734.899 | |
| Interest Coverage Ratio | -12.127 | 0.000 | 0.000 | 0.000 | -734.532 | |
| Short Term Operating Cash Flow Coverage Ratio | -45.571 | -31.781 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -1.719 | -1.297 | -8.940 | -9.426 | -14.501 | |
| Capital Expenditure Coverage Ratio | -307.914 | -12.450 | -5.923 | -13.480 | -51.055 | |
| Dividend Paid And Capex Coverage Ratio | -307.914 | -12.450 | -5.923 | -13.480 | -51.055 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -6.965 | -3.689 | -1.731 | -2.407 | -13.692 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 45.9% | ▼-5.6% | ▼-11.3% |
| Ebit Margin | -1419.8% | ▼-86.8% | ▲37.5% |
| Ebitda Margin | -1365.7% | ▼-81.2% | ▲64.9% |
| Operating Profit Margin | -1425.7% | ▼-75.3% | ▲62.6% |
| Pretax Profit Margin | -1537.4% | ▼-204.4% | ▼-56.5% |
| Continuous Operations Profit Margin | -1537.4% | ▼-204.4% | ▼-56.5% |
| Net Profit Margin | -1537.4% | ▼-204.4% | ▼-56.5% |
| Bottom Line Profit Margin | -1537.4% | ▼-204.4% | ▼-56.5% |
| Current Ratio | 1.056 | ▼-1.801 | ▼-3.853 |
| Quick Ratio | 1.056 | ▼-1.801 | ▼-3.853 |
| Solvency Ratio | -1.176 | ▼-0.189 | ▲1.445 |
| Cash Ratio | 0.806 | ▼-1.905 | ▼-3.616 |
| Price To Earnings Ratio | -5.870 | ▼-1.845 | ▲0.235 |
| Price To Earnings Growth Ratio | -0.391 | ▼-0.566 | ▼-1.281 |
| Forward Price To Earnings Growth Ratio | -0.391 | ▼-0.566 | ▼-1.281 |
| Price To Earnings Diluted Ratio | -5.870 | ▼-1.845 | ▲0.235 |
| Price To Earnings Diluted Growth Ratio | -0.391 | ▼-0.566 | ▼-1.281 |
| Price To Book Ratio | -33.308 | ▼-40.670 | ▼-31.418 |
| Price To Sales Ratio | 91.826 | ▲38.028 | ▲35.620 |
| Price To Free Cash Flow Ratio | -7.091 | ▼-2.299 | ▲0.168 |
| Price To Operating Cash Flow Ratio | -7.114 | ▼-1.937 | ▲0.427 |
| Debt To Assets Ratio | 0.762 | ▲0.367 | ▲0.491 |
| Debt To Equity Ratio | -2.724 | ▼-3.821 | ▼-2.457 |
| Debt To Capital Ratio | 1.580 | ▲1.057 | ▲1.108 |
| Long Term Debt To Capital Ratio | 1.791 | ▲1.311 | ▲1.315 |
| Financial Leverage Ratio | -3.577 | ▼-6.359 | ▼-4.251 |
| Working Capital Turnover Ratio | 0.213 | ▲0.090 | ▲0.115 |
| Operating Cash Flow Ratio | -2.472 | ▼-0.520 | ▲0.930 |
| Operating Cash Flow Sales Ratio | -12.908 | ▼-2.516 | ▼-1.362 |
| Free Cash Flow Operating Cash Flow Ratio | 1.003 | ▼-0.077 | ▼-0.066 |
| Debt Service Coverage Ratio | -9.361 | ▲29.919 | ▲147.347 |
| Interest Coverage Ratio | -12.127 | ▼-12.127 | ▲137.205 |
| Short Term Operating Cash Flow Coverage Ratio | -45.571 | ▼-13.790 | ▼-30.101 |
| Operating Cash Flow Coverage Ratio | -1.719 | ▼-0.422 | ▲5.458 |
| Capital Expenditure Coverage Ratio | -307.913 | ▼-295.464 | ▼-229.749 |
| Dividend Paid And Capex Coverage Ratio | -307.913 | ▼-295.464 | ▼-229.749 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -6.965 | ▼-3.276 | ▼-1.268 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $405.2M | $218.2M | $140.5M | $279.0M | $887.3M | |
| Enterprise value | $419.8M | $192.1M | $108.0M | $207.8M | $795.7M | |
| EV / Sales | 95.13x | 47.38x | 17.89x | 83.52x | 0.00x | |
| EV / Op. cash flow | -7.37x | -4.56x | -1.74x | -3.46x | -16.60x | |
| EV / Free cash flow | -7.35x | -4.22x | -1.49x | -3.22x | -16.28x | |
| EV / EBITDA | -6.96x | -3.69x | -1.73x | -2.41x | -13.69x | |
| Net debt / EBITDA | -0.24x | 0.50x | 0.52x | 0.82x | 1.58x | |
| Current ratio | 1.06x | 2.86x | 2.52x | 3.45x | 14.66x | |
| Income quality | 0.84x | 0.78x | 0.98x | 0.69x | 0.82x | |
| Graham net-net | -$0 | $0 | $0 | $0 | $0 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 99.9% | |
| Interest burden | 108.3% | 100.0% | 100.0% | 100.0% | 100.1% | |
| Working capital | $1.3M | $40.1M | $25.9M | $70.0M | $95.6M | |
| Invested capital | $15.7M | $56.6M | $43.2M | $76.0M | $96.8M | |
| Return on assets | -155.9% | -65.6% | -97.7% | -79.9% | -55.2% | |
| Operating ROA | -99.9% | -74.5% | -75.7% | -83.1% | -87.2% | |
| Return on tangible assets | -155.9% | -65.6% | -97.7% | -79.9% | -55.2% | |
| Return on equity | 557.7% | -182.4% | -155.5% | -117.3% | -60.9% | |
| Return on invested capital | -278.6% | -87.3% | -136.4% | -110.5% | -58.5% | |
| Return on capital employed | -307.3% | -90.0% | -138.1% | -111.2% | -58.8% | |
| Earnings yield | -16.7% | -24.8% | -44.9% | -31.1% | -6.6% | |
| Free cash flow yield | -14.1% | -20.9% | -51.6% | -23.1% | -5.5% | |
| Capex / Op. cash flow | -0.3% | -8.0% | -16.9% | -7.4% | -2.0% | |
| Capex / Depreciation | 7.7% | 172.0% | 1488.1% | 928.5% | 410.0% | |
| Capex / Sales | 4.2% | 83.5% | 173.6% | 179.1% | 0.0% | |
| SG&A / Sales | 624.9% | 658.1% | 530.1% | 1422.8% | 0.0% | |
| R&D / Sales | 900.7% | 792.3% | 655.6% | 2257.2% | 0.0% | |
| Stock comp / Sales | 174.6% | 183.2% | 152.7% | 423.7% | 0.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 0d | 0d | 0d | 0d | |
| Days payables outstanding | 948d | 787d | 1645d | 0d | 0d | |
| Operating cycle | 0d | 0d | 0d | 0d | 0d | |
| Cash conversion cycle | -948d | -787d | -1645d | 0d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-10-14 Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa MALVERN, Pa., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the execution of a licensing agreement with Roots Pharmaceutical, and its strategic partner Al-Dhow International Holding, for the exclusive rights to OCU400, Ocugen''s novel modifier gene therapy for the treatment of Retinitis Pigmentosa (RP), in the Middle East and North Africa (MENA) region.
- 2026-10-08 Did Ocugen, Inc. Insiders Breach their Fiduciary Duties to Shareholders? Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
- 2026-10-07 Hemostemix Announces Full LARTA Approval, Manufacturing Progress and Financing Update Calgary, Alberta--(Newsfile Corp. - October 7, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") announces that it has received full approval from the National Longevity and Regenerative Therapy Board of The Bahamas (LARTA Board), including ethics approval from the LARTA Ethics Committee, for its commercial Phase 1 study of VesCell™as a treatment for angina, vascular dementia and pain. This milestone advances the Company''s clinical development program within The Bahamas'' growing longevity and regenerative-medicine sector.
- 2026-10-06 Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate MALVERN, Pa., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on developing and commercializing novel gene therapies to address blindness diseases, today announced the appointment of Jolanda Crombach, MSc PharmD, as General Manager of the Company''s European affiliate. Ms. Crombach, an accomplished pharmaceutical executive with more than 20 years of industry experience, will lead the Company''s newly established European affiliate, headquartered in Amsterdam, Netherlands.
- 2026-09-30 Ocugen to Participate in Upcoming Scientific Conferences MALVERN, Pa., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology company developing gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming scientific conferences.
- 2026-09-29 Ocugen to Participate in Upcoming October Investor and Industry Conferences MALVERN, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology company developing gene therapies for blindness diseases, today announced that members of its executive leadership team will present at two upcoming investor and industry conferences.
- 2026-09-25 Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa MALVERN, Pa., Sept. 25, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that OCU400 has been granted provisional approval and priority designation from the LARTA Board, the regulatory agency responsible for reviewing and approving longevity and regenerative therapy programs within the Commonwealth of The Bahamas. Ocugen will supply OCU400 through an EAP, with the goal of treating the first RP patient within 90 days, following full LARTA approval.
- 2026-09-16 Ocugen Targets Three Gene Therapy BLA Filings as Retinal Pipeline Advances Ocugen NASDAQ: OCGN is preparing for three planned biologics license application, or BLA, submissions tied to late-stage gene therapy programs targeting retinal diseases, Chairman, Chief Executive Officer and Co-Founder Shankar Musunuri said during a company discussion.
- 2026-09-11 Ocugen: Q3 Data Catalyst In Stargardt Disease Feels Critical Ocugen is advancing three gene therapy programs—OCU400, OCU410ST, and OCU410—targeting major unmet needs in ophthalmology. I assign OCGN a Buy rating, citing strong clinical data, upcoming pivotal trial catalysts, and sufficient cash runway, despite high commercial and execution risk. Key upcoming catalysts include Phase 3 data for OCU400 and OCU410ST (Stargardt) in 2027 and a Phase 3 trial for OCU410 now FDA-cleared.
- 2026-09-02 OCGN Advances Gene Therapy OCU410 In Phase III for Geographic Atrophy Ocugen moves OCU410 into phase III for geographic atrophy, with FDA-aligned study plans. The company expects to file a BLA for OCU410 in 2028.